Rimsys

-1%

est. 2Y upside i

Rank

#2321

Sector

RegTech

Est. Liquidity

~5Y

Data Quality

Data: Low

Equity upside is unattractive: expected return of -1% over 2 years with high risk.

Last updated: July 3, 2026

Bull (10%)+158%

Exit multiple expands to 10x driven by IPO window and category leadership in MedTech RIM. Implied exit value $73M, net of 20% dilution.

Base (50%)+47%

Exit multiple converges to 6x within comp range. Implied exit value $43.8M, net of 20% dilution.

Bear (40%)-100%

Exit multiple compresses to 4x, exit value $29.2M below total funding $32.5M, so common stock recovers nothing per 1x preference.

Est. time to liquidity~5.0 years

Preference Stack Risk

severe

Funding Intensity

12360%

Total funding $32.5M exceeds current valuation $26.3M, so preferred holders have liquidation preference above common.

Dilution Risk

high

Given modest runway from $5M growth financing, a follow-on raise within 2 years could dilute common by ~20%.

Secondary Liquidity

none

No secondary trading activity reported.

Other — 3 roles

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Rimsys's data — designed to show you've done your homework.

1
“How does Rimsys plan to differentiate against Veeva’s expanding RIM capabilities?”
2
“What is the customer acquisition cost and payback period for your subscription model?”
3
“Given the preference stack, what is the realistic timeline to liquidity and what triggers an IPO or acquisition?”

Our model estimates -1% upside. What do you think?

Anonymous. Do not share material non-public information.

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.